Glycyx is a pioneering brand dedicated to harnessing the therapeutic potential of the MOR signaling pathway in the fields of oncology and severe illness. With a simple premise, Glycyx aims to activate the core biological mechanism needed for acute response to injury, preventing immune infiltration into tumors and accelerating disease progression and mortality in severe illnesses. At the forefront of their product lineup is the groundbreaking oral, small molecule MOR antagonist called Axelopran (GLY-001).

This potent compound enables immune infiltration into tumors with minimal toxicity and adverse side effects. With previous successful Phase 2b data showing effective target engagement and good safety and tolerability, Axelopran has great potential for treating multiple cancers. Axelopran has the ability to turn cold tumors hot by blocking the injury response pathway, allowing immune infiltration of the tumor microenvironment.

This breakthrough cancer therapy reduces tumor growth and metastasis while increasing T-cell and NK cell infiltration. It also has the potential to double the response rates of immune checkpoint inhibitors for both overall survival and progression-free survival. Glycyx is supported by a team of experts, including Chief Executive Officer Justin Chickles, Chief Scientific Officer Lorin Johnson, PhD, Chief Business Officer David Taggart, and Chief Medical Advisor Jonathan Moss, MD, PhD.

With a mission to revolutionize cancer treatment, Glycyx is dedicated to making a significant impact in the lives of patients